St John’s Wort (<i>Hypericum perforatum</i>) in Major Depression
J Clin Psychiatry 2009;70(suppl 5):23-27
© Copyright 2017 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
The herb St John’s wort (Hypericum perforatum) has been used for centuries to treat a variety of medical illnesses. In certain areas of Europe, St John’s wort has been a commonly prescribed treatment for depression, but, in the United States, it is available for purchase over the counter as an herbal supplement. Some researchers believe that specific chemical constituents of St John’s wort produce change in depression in a way similar to that of antidepressant medications, yet this hypothesis is problematic. In addition, studies that support the efficacy of St John’s wort in patients with mild-to-moderate depression have limitations that may affect the accuracy of their conclusions. Studies measuring the effect of St John’s wort in major depression have reported conflicting results and need to be reexamined. Because St John’s wort is considered by some to be an alternative to conventional therapies, clinicians need to know whether it is an effective and safe treatment for different levels of severity of depression. Current evidence does not support its use, and,because of potential drug interactions, St John’s wort is not a benign treatment.
From the Department of Psychiatry, and the Mood Disorders Program, Vanderbilt University School of Medicine, Nashville, Tennessee.
This article is derived from the planning teleconference series “The Use of Complementary and Alternative Medicines to Achieve Remission in Major Depressive Disorder,” which was held in May 2009 and supported by an educational grant from Pamlab, LLC.
Dr Shelton is a consultant to Eli Lilly, Evotec, Forest, Gideon-Richter, Janssen, Novartis, Merck, Otsuka, Pamlab, Pfizer, and Repligen; and has received grant/research support from Bristol-Meyers Squibb, Eli Lilly, Evotec, Forest, Janssen, the National Institute of Mental Health, Merck, Novartis, Otsuka, Pamlab, Pfizer, and Repligen.
Corresponding author: Richard C. Shelton, MD, The Village at Vanderbilt, 1500 21st Ave South, Suite 2200, Nashville, TN 37212-8646 (email@example.com).